MedTrace Logo

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01032915 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2015-11-05

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

Conditions

  • Non-infectious Uveitis

Interventions

BIOLOGICAL

AIN457

AIN457 300mg s.c weekly for 3 weeks then every 2 weeks

BIOLOGICAL

AIN457

AIN457 300mg s.c at baseline and Week 2 then every 4 weeks

BIOLOGICAL

AIN457

AIN457 150mg s.c at baseline and Week 2 then every 4 weeks

DRUG

Placebo

Placebo s.c weekly for 3 weeks then every 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Brazil
  • Germany
  • India
  • Israel
  • Italy
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032915 on ClinicalTrials.gov